MA27182A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Info

Publication number
MA27182A1
MA27182A1 MA27840A MA27840A MA27182A1 MA 27182 A1 MA27182 A1 MA 27182A1 MA 27840 A MA27840 A MA 27840A MA 27840 A MA27840 A MA 27840A MA 27182 A1 MA27182 A1 MA 27182A1
Authority
MA
Morocco
Prior art keywords
ppar
activity
compounds
thiazole
modulate
Prior art date
Application number
MA27840A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Chitase Lee
Noe Ouano Erasga
Andrew George Geyer
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27182A1 publication Critical patent/MA27182A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

DEPOSANT Société dite: WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 7 Mars 2002 60/362,400 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole et d'oxazole qui modulent l'activité de PPAR La présente invention décrit des composés qui modifient l'activité de PPAR. La présente invention décrit également des sels pharmaceutiquement acceptables des composés, des compositions pharmaceutiquement acceptables comprenant les composés ou leurs sels, et des méthodes pour leur utilisation comme agents thérapeutiques pour le traitement ou la prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention décrit également un procédé pour la préparation des composés décrits.
MA27840A 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar. MA27182A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
MA27182A1 true MA27182A1 (fr) 2005-01-03

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27840A MA27182A1 (fr) 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Country Status (29)

Country Link
US (1) US6833380B2 (fr)
EP (1) EP1485091A1 (fr)
JP (1) JP2005524665A (fr)
KR (1) KR20040091694A (fr)
CN (1) CN1638768A (fr)
AP (1) AP2004003123A0 (fr)
AR (1) AR038883A1 (fr)
AU (1) AU2003207891A1 (fr)
BR (1) BR0308221A (fr)
CA (1) CA2476580A1 (fr)
CO (1) CO5601013A2 (fr)
EA (1) EA200401160A1 (fr)
EC (1) ECSP045275A (fr)
GT (1) GT200300053A (fr)
HR (1) HRP20040810A2 (fr)
IL (1) IL163768A0 (fr)
IS (1) IS7399A (fr)
MA (1) MA27182A1 (fr)
MX (1) MXPA04008624A (fr)
NO (1) NO20044245L (fr)
OA (1) OA12781A (fr)
PA (1) PA8568701A1 (fr)
PE (1) PE20031010A1 (fr)
PL (1) PL372971A1 (fr)
TN (1) TNSN04167A1 (fr)
TW (1) TW200400027A (fr)
UY (1) UY27704A1 (fr)
WO (1) WO2003074052A1 (fr)
ZA (1) ZA200406491B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
EP1745014B1 (fr) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Nouveaux composes, leur preparation et leur utilisation
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1749000A4 (fr) * 2004-05-25 2009-12-30 Metabolex Inc Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (fr) 2008-10-16 2016-06-28 Addex Pharma S.A. Derives d'indole et de benzomorpholine en tant que modulateurs des recepteurs metabotropiques du glutamate
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (fr) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
WO1997028149A1 (fr) 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
EE03765B1 (et) 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
US6930120B2 (en) 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
HUP0400023A2 (hu) 2001-05-29 2004-04-28 Kyoto Pharmaceutical Industries, Ltd. Új heterociklusos származékok és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
PL367077A1 (en) 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
WO2002102780A1 (fr) 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
HRP20040810A2 (en) 2004-12-31
PA8568701A1 (es) 2003-11-12
NO20044245L (no) 2004-10-06
IS7399A (is) 2004-08-12
ZA200406491B (en) 2006-05-31
US6833380B2 (en) 2004-12-21
PL372971A1 (en) 2005-08-08
ECSP045275A (es) 2004-10-26
PE20031010A1 (es) 2003-12-12
JP2005524665A (ja) 2005-08-18
OA12781A (en) 2006-07-07
BR0308221A (pt) 2005-01-04
CA2476580A1 (fr) 2003-09-12
CN1638768A (zh) 2005-07-13
CO5601013A2 (es) 2006-01-31
EA200401160A1 (ru) 2005-02-24
WO2003074052A1 (fr) 2003-09-12
MXPA04008624A (es) 2004-12-06
TW200400027A (en) 2004-01-01
TNSN04167A1 (fr) 2007-03-12
US20030207916A1 (en) 2003-11-06
AP2004003123A0 (en) 2004-09-30
KR20040091694A (ko) 2004-10-28
GT200300053A (es) 2003-10-10
AU2003207891A1 (en) 2003-09-16
UY27704A1 (es) 2003-10-31
EP1485091A1 (fr) 2004-12-15
AR038883A1 (es) 2005-02-02
IL163768A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
MA27182A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27181A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA27568A1 (fr) Derives de pyrrolopyrimidine
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
MA26997A1 (fr) Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA27135A1 (fr) Agents antidiabetiques oraux
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
IL152337A0 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
SE9903997D0 (sv) New compounds
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
MA26953A1 (fr) Derives de pipérazine pontés.